Impact of the SARS-CoV-2 pandemic on lung cancer survival in England: An analysis of the rapid cancer registration dataset

Helen Morgan; Savannah Gysling; Neal Navani; David Baldwin; Richard Hubbard; Emma O'Dowd

doi:10.1136/thorax-2022-219593

Impact of the SARS-CoV-2 pandemic on lung cancer survival in England: An analysis of the rapid cancer registration dataset

Helen Morgan, Savannah Gysling, Neal Navani, David Baldwin, Richard Hubbard, Emma O'Dowd

Research output: Journal Publication › Article › peer-review

Abstract

Early changes in lung cancer care can affect survival. Given the decrease in diagnosis during lockdowns, we calculated their impact on survival using National Lung Cancer Audit data. Percentage survival and HRs for death were compared between 2019 and lockdown periods of 2020. Decreased survival was observed from the first national lockdown onwards and within 90 days of diagnosis. HRs were highest for people diagnosed at the end of 2020 at 1.26 (95% CI 1.20 to 1.32) for death within 90 days and 1.51 (95% CI 1.42 to 1.60) for death between 91 and 270 days. Further work is needed on measures to mitigate this impact.

Original language	English
Pages (from-to)	83-85
Number of pages	3
Journal	Thorax
Volume	79
Issue number	1
DOIs	https://doi.org/10.1136/thorax-2022-219593
Publication status	Published - 1 Jan 2024
Externally published	Yes

Keywords

COVID-19
clinical epidemiology
lung cancer

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1136/thorax-2022-219593

Cite this

@article{c697c0c3f04c46bba02ecaf25c8538ac,

title = "Impact of the SARS-CoV-2 pandemic on lung cancer survival in England: An analysis of the rapid cancer registration dataset",

abstract = "Early changes in lung cancer care can affect survival. Given the decrease in diagnosis during lockdowns, we calculated their impact on survival using National Lung Cancer Audit data. Percentage survival and HRs for death were compared between 2019 and lockdown periods of 2020. Decreased survival was observed from the first national lockdown onwards and within 90 days of diagnosis. HRs were highest for people diagnosed at the end of 2020 at 1.26 (95% CI 1.20 to 1.32) for death within 90 days and 1.51 (95% CI 1.42 to 1.60) for death between 91 and 270 days. Further work is needed on measures to mitigate this impact.",

keywords = "COVID-19, clinical epidemiology, lung cancer",

author = "Helen Morgan and Savannah Gysling and Neal Navani and David Baldwin and Richard Hubbard and Emma O'Dowd",

year = "2024",

month = jan,

day = "1",

doi = "10.1136/thorax-2022-219593",

language = "English",

volume = "79",

pages = "83--85",

journal = "Thorax",

issn = "0040-6376",

publisher = "BMJ Publishing Group",

number = "1",

}

TY - JOUR

T1 - Impact of the SARS-CoV-2 pandemic on lung cancer survival in England

T2 - An analysis of the rapid cancer registration dataset

AU - Morgan, Helen

AU - Gysling, Savannah

AU - Navani, Neal

AU - Baldwin, David

AU - Hubbard, Richard

AU - O'Dowd, Emma

PY - 2024/1/1

Y1 - 2024/1/1

N2 - Early changes in lung cancer care can affect survival. Given the decrease in diagnosis during lockdowns, we calculated their impact on survival using National Lung Cancer Audit data. Percentage survival and HRs for death were compared between 2019 and lockdown periods of 2020. Decreased survival was observed from the first national lockdown onwards and within 90 days of diagnosis. HRs were highest for people diagnosed at the end of 2020 at 1.26 (95% CI 1.20 to 1.32) for death within 90 days and 1.51 (95% CI 1.42 to 1.60) for death between 91 and 270 days. Further work is needed on measures to mitigate this impact.

AB - Early changes in lung cancer care can affect survival. Given the decrease in diagnosis during lockdowns, we calculated their impact on survival using National Lung Cancer Audit data. Percentage survival and HRs for death were compared between 2019 and lockdown periods of 2020. Decreased survival was observed from the first national lockdown onwards and within 90 days of diagnosis. HRs were highest for people diagnosed at the end of 2020 at 1.26 (95% CI 1.20 to 1.32) for death within 90 days and 1.51 (95% CI 1.42 to 1.60) for death between 91 and 270 days. Further work is needed on measures to mitigate this impact.

KW - COVID-19

KW - clinical epidemiology

KW - lung cancer

UR - http://www.scopus.com/inward/record.url?scp=85177493798&partnerID=8YFLogxK

U2 - 10.1136/thorax-2022-219593

DO - 10.1136/thorax-2022-219593

M3 - Article

C2 - 37932123

AN - SCOPUS:85177493798

SN - 0040-6376

VL - 79

SP - 83

EP - 85

JO - Thorax

JF - Thorax

IS - 1

ER -

Impact of the SARS-CoV-2 pandemic on lung cancer survival in England: An analysis of the rapid cancer registration dataset

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this